Alzheimer’s disease, breast cancer, diabetes and obesity affect millions of people, at all income levels, around the globe. 

A partnership between healthcare enterprise Centene Corp. and Washington University School of Medicine in St. Louis aims to accelerate research into treatment and prevention of these diseases.

Over a 10-year period, Centene will fund up to $100 million in research to galvanize the School of Medicine’s Personalized Medicine Initiative. 

The investment will leverage the university’s cutting-edge research, biomedical capabilities, state-of-the-art technologies and internationally known scientists in the areas of the microbiome, immunomodulatory therapies, cancer genomics, neurodegeneration, cellular reprogramming, chemical biology, informatics and others. The funds also will strengthen resources at more than a dozen centers and institutes at the School of Medicine.

The ultimate goal is disease treatment and prevention that is customized to the individual  and affordable and accessible for all.